Maegim한국어

삼아제약

009300KOSDAQSector: Pharma & Biotech
₩12,380▼ 1.12%Market cap ₩78.9BAs of Jul 21, 2026 close · updated once daily
A
Grade A72.6 ptsTop 7% of 2,523 stocks
Financial strength
84.1
Growth momentum
22.5
Price attractiveness
95.3

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

84.1
How much debt does it carry relative to equity?
Debt-to-equity ratio
8.3%
✓ Above median · Top 9.6% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
978.1%
✓ Above median · Top 14.4% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
14.1%
✓ Above median · Top 13% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
5.7%
✓ Above median · Top 26.6% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

22.5
How much did revenue grow in a year?
Revenue growth (YoY)
-18.6%
✗ Below median · Top 87.4% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
-1.6%
✗ Below median · Top 71.7% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-55.1%
✗ Below median · Top 84.6% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-39.9%
✗ Below median · Top 66.4% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

95.3
Is the price expensive relative to earnings?
P/E (price-to-earnings)
6.1x
✓ Above median · Top 5.1% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.35x
✓ Above median · Top 4.3% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15